Abstract：
OBJECTIVE:Determine whether MRI activity 6 months after treatment initiation in the Controlled High-Risk Subjects Avonex® Multiple Sclerosis Prevention Study (CHAMPS) predicted progression to clinically definite multiple sclerosis (CDMS) over the subsequent 30 months in intramuscular interferon beta-1a (IM IFNβ-1a)-treated patients vs placebo-treated patients. METHODS:CHAMPS patients were randomized to once-weekly IM IFNβ-1a 30 μg or placebo for up to 36 months. MRI was performed every 6 months until CDMS confirmation. Patient groups were defined based on new T2 and/or Gd+ lesions at 6 months. RESULTS:Thirteen IM IFNβ-1a patients (6.7%) and 24 placebo patients (12.6%) developed CDMS prior to month 6 and did not undergo the 6-month MRI. At 6 months, 29.7% of IM IFNβ-1a-treated patients vs 40.9% of placebo-treated patients were defined as having high MRI activity levels (≥2 new T2 and/or ≥2 Gd+ lesions). In this subgroup, estimated cumulative probabilities of CDMS were similar between groups (HR=0.88 [0.44-1.77], p=0.7227). A significant treatment response was seen for patients with <2 new T2 and <2 Gd+ lesions at 6 months (HR=0.39 [0.19-0.82], p=0.0120). CONCLUSION:MRI scans 6 months after IM IFNβ-1a initiation in CIS patients predict early treatment non-response. Standardized scanning and monitoring may facilitate early disease management.
journal_name
Mult Scler Relat Disordjournal_title
Multiple sclerosis and related disordersauthors
Kinkel RP,Simon JH,O'Connor P,Hyde R,Pace Adoi
10.1016/j.msard.2014.08.003subject
Has Abstractpub_date
2014-11-01 00:00:00pages
712-9issue
6eissn
2211-0348issn
2211-0356pii
S2211-0348(14)00102-3journal_volume
3pub_type
杂志文章,随机对照试验abstract：BACKGROUND:The presence of white mater lesions in the central nervous system forces the differential diagnosis between multiple sclerosis (MS) and Anderson-Fabry disease (FD). Due to the type of inheritance, linked to the X chromosome, the diagnosis of FD is especially difficult in women. Tissue´s deposits of globotria...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2019.101466
更新日期：2020-02-01 00:00:00
abstract：INTRODUCTION:All people with progressive MS in the United Kingdom should have access to physiotherapy through the National Health Service (NHS). However levels of access and delivery are unknown. Furthermore there is no research on perceived efficacy of physiotherapy or the use of complementary and alternative medicine...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2017.01.002
更新日期：2017-02-01 00:00:00
abstract：BACKGROUND:Little is known about the factors associated with the selection of Disease Modifying Agents (DMA) for the management of Multiple Sclerosis (MS) since the introduction of oral DMAs in 2010. OBJECTIVES:To examine the factors associated with initiation of oral DMAs in patients with MS using data from electroni...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102334
更新日期：2020-10-01 00:00:00
abstract：BACKGROUND:Cognitive deficits, especially in attention, are common in persons with MS (PwMS) and are associated with clinically meaningful outcomes, such as work disability and lower quality of life (QOL). In this study, we aimed to determine whether Cogmed Working Memory Training (CWMT) improves attention/working memo...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2021.102770
更新日期：2021-01-17 00:00:00
abstract：:Neural cell adhesion molecule (NCAM) has been studied extensively. But it is only in recent times that interest in this molecule has shifted to conditions such as Alzheimer's disease, Multiple Sclerosis and Schizophrenia, focusing on its role in neurodegeneration and abnormal neurodevelopment. NCAM is important in neu...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章,评审
doi：10.1016/j.msard.2012.08.002
更新日期：2013-01-01 00:00:00
abstract：BACKGROUND:Neuromyelitis optica spectrum disorder (NMOSD) is a complex disease characterized by a severe inflammation of the central nervous system (CNS). This disease typically manifests with recurrent optic neuritis (ON) and acute transverse myelitis (ATM). The clinical and radiological spectrum of NMOSD is little kn...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102208
更新日期：2020-09-01 00:00:00
abstract：BACKGROUND:Fatigue is a common impairment in a wide range of disorders. Numerous fatigue scales have been designed in an attempt to quantify this impairment without any clear distinction between them. The International Classification of Functioning, Disability and Health (ICF) is a useful tool for content comparison of...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102596
更新日期：2020-11-01 00:00:00
abstract：BACKGROUND:Natural history studies have typically focused on non-modifiable factors as predictors of disability progression in multiple sclerosis (MS). Weight status has emerged as a correlate of disability status in cross-sectional studies of persons with MS and represents a possible modifiable predictor of disability...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2012.02.004
更新日期：2012-07-01 00:00:00
abstract：BACKGROUND:Olfactory dysfunction is a known clinical feature of multiple sclerosis (MS). Some studies have shown that odor identification impairment is an essential feature associated with cognitive function in MS. This study investigates the relationship between olfactory identification and the disease state, includin...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2019.101507
更新日期：2020-02-01 00:00:00
abstract：BACKGROUND:Fingolimod (Gilenya, Novartis, Basel Switzerland) 0.5 mg orally once-daily is widely used for relapsing-remitting multiple sclerosis. Patients are usually screened four months after starting fingolimod for fingolimod-associated macular oedema (FAME). Large registration trials with stringent eligibility crite...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102125
更新日期：2020-07-01 00:00:00
abstract：BACKGROUND:Coronavirus disease 19 (COVID-19) is a novel disease entity that is spreading throughout the world. It has been speculated that patients with comorbidities and elderly patients could be at high risk for respiratory insufficiency and death. Immunosuppression could expose infected patients to even higher risks...
journal_title：Multiple sclerosis and related disorders
pub_type：
doi：10.1016/j.msard.2020.102120
更新日期：2020-07-01 00:00:00
abstract：BACKGROUND:Cognitive impairment is common in multiple sclerosis (MS), but deficits tend to be more pronounced in progressive MS, negatively impacting daily functional capacity. Despite this, most cognitive rehabilitation (CR) interventions to date have focused on relapsing-remitting MS (RRMS). Moreover, information on ...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.101932
更新日期：2020-01-07 00:00:00
abstract：BACKGROUND:Multiple sclerosis (MS) is the most common chronic inflammatory demyelinating disease of the central nervous system (CNS), and whether herpes simplex virus (HSV) infection is associated with the development of MS remains controversial. We aimed to investigate potential associations between MS or clinically i...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102633
更新日期：2020-11-19 00:00:00
abstract：BACKGROUND:The epidemiology of multiple sclerosis (MS) and neuromyelitis optica (NMO) remains to be clarified or updated in many parts of Asia. This study aims to investigate the epidemiology and comorbidities of MS and NMO during 2001-2015 in Taiwan. METHODS:We conducted a retrospective nationwide population-based st...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102425
更新日期：2020-10-01 00:00:00
abstract：INTRODUCTION:The introduction of several new disease-modifying therapies (DMTs) to the field of Multiple Sclerosis (MS) treatment requires that MS healthcare providers have a comprehensive understanding of the implications of each new treatment option in order to select the treatment that best suits their patient. An i...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2015.05.008
更新日期：2015-07-01 00:00:00
abstract：:The Acceptance of Chronic Health Conditions Scale was developed to measure acceptance in chronic health conditions like multiple sclerosis (MS) and has been translated into Swedish (The Swedish Acceptance of Chronic Health Conditions Scale). The purpose of the present study was to evaluate construct validity and test-...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2019.07.033
更新日期：2019-10-01 00:00:00
abstract：BACKGROUND:Neuromyelitis optica (NMO) is a disabling inflammatory condition that targets astrocytes in the optic nerves and spinal cord. Recent advances led to the individualization of a set of conditions now referred as NMO spectrum disorder (NMOSD). OBJECTIVE:To describe the prevalence and characteristics of NMO SD ...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2015.12.005
更新日期：2016-03-01 00:00:00
abstract：:Lay-members of the public are often involved in grant and ethics review panels. Furthermore grant applications/reports all require some form of lay summary. In response to critical remarks from people with multiple sclerosis (MS) about using the term 'sufferer' as a descriptor, a series of surveys using the internet/s...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2013.06.010
更新日期：2014-01-01 00:00:00
abstract：BACKGROUND:High salt intake may be associated with pro-inflammatory changes in the immune response, and increased clinical and MRI activity in adults with relapsing-remitting multiple sclerosis. OBJECTIVE:We sought to determine if dietary salt intake is associated with pediatric-onset MS risk in a multicenter, case-co...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章,多中心研究
doi：10.1016/j.msard.2016.02.011
更新日期：2016-03-01 00:00:00
abstract：:Multiple Sclerosis (MS) is an autoimmune disease in which lymphocytes target putative myelin antigens in the CNS, causing inflammation and neurodegeneration. Fingolimod (FTY720) is an immunosuppressive drug used as a second line therapy for relapsing forms of MS due to its safety profile and good response to treatment...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2017.05.004
更新日期：2017-11-01 00:00:00
abstract：BACKGROUND:Myelin oligodendrocyte glycoprotein (MOG) is an important marker on the surface of oligodendrocytes and is associated with many demyelinating diseases. Recently, MOG-IgG-associated encephalomyelitis (MOG-EM) has been proposed as a disease entity with a preliminary diagnosis standard. Some patients with lung ...
journal_title：Multiple sclerosis and related disorders
pub_type：
doi：10.1016/j.msard.2020.102064
更新日期：2020-07-01 00:00:00
abstract：:Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) commonly complicated by cognitive impairment. Unfortunately, no medical therapy has been proved to improve cognitive problems in these patients. This meta-analysis investigated the effectiveness of different categories...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102478
更新日期：2020-11-01 00:00:00
abstract：BACKGROUND:Cognitive impairment is highly prevalent in multiple sclerosis (MS). Due to the lack of specialized neuropsychological resources in many MS clinics, a brief cognitive monitoring tool that can be administered by other MS clinic staff is needed. BICAMS (Brief International Cognitive As-sessment for Multiple Sc...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2019.101458
更新日期：2020-01-01 00:00:00
abstract：BACKGROUND:Multiple reports have described the proportion of Th17 cells in peripheral blood and serum levels of Th17-related cytokines in patients with multiple sclerosis (MS). To clarify the status of Th17 cells and Th17-related cytokines in MS patients, we did a meta-analysis of the results published previously to as...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章,meta分析,评审
doi：10.1016/j.msard.2017.09.003
更新日期：2017-11-01 00:00:00
abstract：BACKGROUND:Whilst there is a broad selection of drugs licensed as disease modifying treatments (DMTs) for people with relapsing multiple sclerosis (pwRMS), access to DMTs remains restricted, particularly for people with progressive MS (pwPMS). Cladribine has shown efficacy at all stages of MS. Following withdrawal from...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2018.11.001
更新日期：2019-01-01 00:00:00
abstract：BACKGROUND:There are limited data on the impact of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on people with multiple sclerosis (MS). OBJECTIVE:To better understand SARS-CoV-2 infection in ocrelizumab-treated people with MS. METHODS:Internal Roche/Ge...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102725
更新日期：2020-12-30 00:00:00
abstract：BACKGROUND:As vaccines for the coronavirus become available, it will be important to know the rate of COVID-19 vaccine acceptability in adults with multiple sclerosis (MS), given that vaccination will be a key strategy for preventing SARS-CoV-2 infections. Using a national sample of adults with MS in the United States ...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2021.102788
更新日期：2021-01-22 00:00:00
abstract：AIM OF THE STUDY:To investigate adherence to disease modifying therapy (DMT) in Lithuanian population of multiple sclerosis patients and factors associated to it. METHODS:Patients receiving one of the following DMT's: Interferon β 1a (Rebif) 44 micrograms three times a week subdermally (s/c) or Interferon β 1a (Avonex...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2017.02.016
更新日期：2017-04-01 00:00:00
abstract：BACKGROUND:Multiple Sclerosis (MS) pathology is likely to disrupt central auditory pathways, thereby affecting an individual's ability to discriminate speech from noise. Despite the importance of speech discrimination in daily communication, it's characterization in the context of MS remains limited. This cross-section...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2020.102608
更新日期：2020-11-01 00:00:00
abstract：OBJECTIVE:To examine whether cognitive and physical fatigue are differentially associated with problems in self-care, mobility, relationships, participation, psychological well-being, and quality of life in people with multiple sclerosis. METHODS:A cross-sectional study involving seventy-four community-dwelling people...
journal_title：Multiple sclerosis and related disorders
pub_type： 杂志文章
doi：10.1016/j.msard.2019.03.024
更新日期：2019-06-01 00:00:00
